Since the co-occurrence of BCR::ABL1 kinase domain mutations and cancer gene mutations is found in a high proportion of patients with TKI resistance, we should not consider resistance to be either BCR::ABL1-dependent or BCR::ABL1-independent; rather, resistance mechanisms may act interdependently to drive disease progression. This evidence concerns the gene BCR and cancer.